Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Net Income

Bottom-line profit after all expenses, interest, and taxes.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$19.63M, compared with -$13.15M a year earlier. Trailing-twelve-month net income was -$84.74M.

Context

  • Net income amounted to 132642.4% of revenue in FY2025, up 124676.6 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 12 analysts of -$32.99M (+57.8%) for the fiscal year ending Dec 2026, a step up from the -122.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.63M-43.1% QoQ
Last fiscal yearDec 2025
-$78.26M-122.8% YoY
LTMMar 2026
-$84.74M-216.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-49.3%-22.4%+26.9 pp
1 year-122.8%+57.8%+180.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(78.26M) USD
Year-over-year change
-122.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -216.1% is the 8th highest of 10, against a peer median of +4.0%.
  • Net income amounts to 143627.1% of revenue for AVTX, versus a peer median of 223.6%.
AVTX Competitors
Net Income for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$33.24M USD+155.6%—61.9%
ANABAnaptysBio, Inc.LTM Mar 2026-$26.79M USD+81.0%—11.5%
IFRXInflaRx N.V.LTM Mar 2026-€42.91M EUR+4.0%—146303.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024-€46.27M EUR-306.2%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M USD+46.5%—832.6%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026-$78.15M USD-310.3%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$84.74M USD-216.1%—143627.1%
IMUXImmunic, Inc.LTM Mar 2026-$104.29M USD-8.2%——
XNCRXencor, Inc.LTM Jun 2026-$163.33M USD+8.8%—155.6%
SYRESpyre Therapeutics, Inc.LTM Sep 2026-$263.86M USD-77.1%—291.6%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AVTX) —+4.0%—223.6%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.